GeneDx Holdings Corp. (WGS)
| Market Cap | 2.65B |
| Revenue (ttm) | 305.45M |
| Net Income (ttm) | -52.29M |
| Shares Out | 28.07M |
| EPS (ttm) | -1.94 |
| PE Ratio | n/a |
| Forward PE | 99.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 476,897 |
| Open | 97.33 |
| Previous Close | 96.44 |
| Day's Range | 91.88 - 97.99 |
| 52-Week Range | 8.49 - 115.60 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | 82.60 (-12.44%) |
| Earnings Date | Apr 28, 2025 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company is headquartered in Stamford, Connecticut. [Read more]
Financial Performance
In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $82.6, which is a decrease of -12.44% from the latest price.
News
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced today they have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025.
GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its scientific contributions will be presented at th...
GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support ...
GeneDx Holdings: There Is Upside Potential, But Price Tag Is Rich
GeneDx Holdings Corp. is delivering strong revenue growth, but it is still burning cash, which makes me hesitant. At 7x sales, WGS stock feels expensive, given its current financials. If GeneDx can pr...
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing.
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the American Journal of Human Genetics published peer-reviewed research from the Seqfirst-neo study.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy'
GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and reduci...
GeneDx CEO on pediatric genetic testing, future of genome sequencing and share surge
Katherine Stueland, GeneDx CEO, joins 'Closing Bell' to discuss company earnings and the future of genome sequencing.
GeneDx Holdings Corp. (WGS) Q4 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2024 Results Conference Call February 18, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Execu...
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announces a ultraRapid Genome, offering accelerated genomic insights for neonatal and pediatric patients in as soon as 2 days.
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), today announced that company management will participate in the TD Cowen Health Care Conference from March 3-5 in Boston, MA.
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...